I don't think, based on what we know now, that CFS (and certainly not ME) is ahead of fibro in prevalence or incidence. However there seems to be some consensus from our experts that its far too underdiagnosed, even while its also misdiagnosed. Where the balance lies is difficult to be sure about.
Workwell has a long history of testing patients with many diseases. Not all of it is published, but has been commented on in various video presentations. Their core business was functional capacity evaluation. We need formal published studies, but until then we can still cite their experience. Some issues do arise because what is considered mild, moderate, severe etc. varies a lot, regardless of the disease.
Biomarkers will change everything. I suspect PEM might not be unique to one disease, but possibly unique to two versions of ME, whether they be two different diseases or one disease with two manifestations.
With the potential axing of CDC funding for ME/CFS we may have to deal with political considerations where social values about the perceived importance of ME/CFS have to be factored into advocacy. This has always been a huge issue, but it could become critical.
We need a rallying cry in advocacy. I am hoping Rituximab could be it. Just two to three years and we might have something that will change public perception. With MS is was MRIs, I think. With gastric ulcers it was Helicobacter pylori. With us it will be something, and the next likely something is Rituximab. The global medical community is still largely ignoring the 2 day CPET findings.